Duncombe C, Bloch M, Quan D; Australasian Society for HIV Medicine. Conference.
Annu Conf Australas Soc HIV Med. 1994 Nov 3-6; 6: 261 (unnumbered poster).
Holdsworth House General Practice, Darlinghurst NSW.
STUDY OBJECTIVES: To assess the safety and efficacy of Ketoconazole applied as a 2% shampoo in the treatment of seborrhoeic dermatitis in patients with concomitant HIV infection. METHODOLOGY: 46 HIV positive patients with moderate to severe facial and scalp seb. derm. applied Ketoconazole as a 2% shampoo to the scalp massaging the lather over the face and other affected areas leaving contact with the skin for five minutes. Treatment was for three consecutive days then twice weekly for four weeks. SUMMARY OF RESULTS: 31 patients reported complete resolution of scaling, erythema and itch. 13 patients reported a marked improvement in symptoms. Two patients reported a moderate improvement. There were no adverse events reported and all participants completed the four week course of treatment. CONCLUSION: Seborrhoeic dermatitis is a common condition in people with HIV infection. There appears to be a causative relationship between the yeast Pityrosporum and seborrhoeic dermatitis, hence the rationale for using the topical anti-fungal agent Ketoconazole. The shampoo as a delivery agent is 'patient-friendly' and compliance was good. Ketoconazole shampoo is an effective and safe treatment for seborrhoeic dermatitis. Immunosuppressed patients often will need maintenance therapy.
Publication Types:
Keywords:
- Dermatitis, Seborrheic
- HIV Infections
- HIV Seropositivity
- Humans
- Ketoconazole
- Malassezia
- Scalp
- Scalp Dermatoses
- organization & administration
- therapy
Other ID:
UI: 102212370
From Meeting Abstracts